Novolin 70/30 TID is NOT the appropriate regimen for this patient
Novolin 70/30 should NOT be prescribed three times daily with meals for a patient on active chemotherapy with uncontrolled blood glucose. The FDA label explicitly states that Novolin 70/30 is "typically dosed twice daily (with each dose intended to cover 2 meals or a meal and a snack)" 1. More importantly, the fixed 70:30 ratio of intermediate-acting to short-acting insulin does not allow for the flexible basal versus prandial dose adjustments needed in chemotherapy patients, particularly those with steroid-induced hyperglycemia 1.
Why This Regimen Fails in Chemotherapy Patients
Chemotherapy patients—especially those receiving corticosteroids—require insulin regimens that can be independently adjusted for basal and prandial coverage. The pharmacokinetics of steroids like dexamethasone cause peak hyperglycemia 7-9 hours after dosing, with elevations persisting through late morning and afternoon 2. A fixed-ratio premixed insulin cannot accommodate these variable glycemic patterns.
For patients on high-dose steroids with chemotherapy (like hyper-CVAD protocols), evidence demonstrates that basal-bolus insulin therapy distributed as 25% basal and 75% prandial insulin at 1.0-1.3 units/kg/day is the effective approach 3. This allows independent titration of each component based on glucose patterns.
The Correct Approach for This Patient
Start with a basal-bolus regimen using separate insulins:
- Calculate total daily dose: 0.4-0.5 units/kg/day for glucose 140-400 mg/dL (use 0.2-0.3 units/kg if age ≥70 or GFR <60) 4
- Distribute as 50% basal insulin (glargine or detemir once or twice daily) and 50% nutritional insulin (rapid-acting analog divided equally before three meals) 4
- Add correction insulin using a sliding scale appropriate to insulin sensitivity 4
If the patient is receiving corticosteroids specifically, consider NPH insulin dosed to match the steroid's glycemic profile—typically given in the morning for once-daily steroids 5, 2. For dexamethasone, intermediate-acting insulin or additional prandial coverage at lunch and dinner addresses the afternoon hyperglycemia peak 6, 2.
Critical Pitfalls to Avoid
Never use premixed insulins when independent basal-prandial adjustment is needed. The ADA guidelines explicitly note that in premixed formulations like Novolin 70/30, "the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments" 1.
Avoid sliding scale insulin (SSI) as the sole therapy. Guidelines strongly recommend against prolonged SSI use alone in hospitalized patients, as it increases hyperglycemia risk 3-fold 4.
Monitor for hypoglycemia when steroids are tapered or discontinued. As steroids are the primary driver of hyperglycemia, any steroid dose adjustment necessitates immediate insulin regimen review 2.
The proposed 18 units total daily dose is likely inadequate for uncontrolled hyperglycemia in a chemotherapy patient. Even at 0.3 units/kg (conservative dosing), this would only be appropriate for a 60 kg patient—and chemotherapy patients often require higher doses, particularly with concurrent steroids 3.
Alternative Consideration
If simplicity is paramount and the patient cannot manage multiple daily injections, twice-daily NPH with regular insulin (self-mixed or premixed 70/30) remains an option 7, 5, but this is still only twice daily, not three times daily. The most recent ADA guidelines suggest that when adding prandial insulin to NPH, "consider initiation of a self-mixed or premixed insulin regimen to decrease the number of injections required" 5—but this refers to twice-daily dosing, not TID.
Bottom line: Use separate basal and prandial insulins with independent titration capability. If premixed insulin is chosen for convenience, use it twice daily as labeled, not three times daily.